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ATP-binding cassette (ABC) transporters facilitate unidirectional translocation of chemically diverse sub-
stances, ranging from peptides to lipids, across cell or organelle membranes. In peroxisomes, a subfamily
of four ABC transporters (ABCD1 to ABCD4) has been related to fatty acid transport, because patients
with mutations in ABCD1 (ALD gene) suffer from X-linked adrenoleukodystrophy (X-ALD), a disease
characterized by an accumulation of very-long-chain fatty acids (VLCFAs). Inactivation in the mouse of
the abcd1 gene leads to a late-onset neurodegenerative condition, comparable to the late-onset form of
X-ALD [Pujol, A., Hindelang, C., Callizot, N., Bartsch, U., Schachner, M. and Mandel, J.L. (2002) Late
onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyelo-
neuropathy. Hum. Mol. Genet., 11, 499–505.]. In the present work, we have generated and characterized
a mouse deficient for abcd2, the closest paralog to abcd1. The main pathological feature in abcd22/2
mice is a late-onset cerebellar and sensory ataxia, with loss of cerebellar Purkinje cells and dorsal root
ganglia cell degeneration, correlating with accumulation of VLCFAs in the latter cellular population.
Axonal degeneration was present in dorsal and ventral columns in spinal cord. We have identified
mitochondrial, Golgi and endoplasmic reticulum damage as the underlying pathological mechanism,
thus providing evidence of a disturbed organelle cross-talk, which may be at the origin of the pathological
cascade.
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INTRODUCTION
Peroxisomes are subcellular organelles present in most
eukaryotic cells (1). They fulfill a number of essential cellular
functions, including the catabolism of pipecolic, phytanic and
very-long-chain fatty acids (VLCFAs) and the biosynthesis of
plasmalogens (ether lipids) and bile acids (2). The importance
of peroxisomes for normal cellular functioning is illustrated by
the peroxisome biogenesis disorders (PDB) (Zellweger syn-
drome, neonatal adrenoleukodystrophy and infantile Refsum’s
disease). PBDs are characterized by a loss of functional peroxi-
somes, resulting in the presence of matrix enzymes in the
cytosol because of mutations in one of the many so-called
PEX genes, which encode proteins (peroxins) essential for
proper peroxisome biogenesis (3,4). In Zellweger syndrome,
the most severe of these disorders, infants exhibit neonatal
hypotonia, hepatic dysfunction and seizures associated with
neuronal migration defects (McKusick 214100). Indeed, in
the nervous system, peroxisomes have been localized in cell
bodies, axons, dendrites, neurites and presynaptic axon term-
inals (5–8) and active growth cones (9), suggesting an active
metabolic role for peroxisomes in guidance cues, in outgrowth
and in maintenance of neurites.
ATP-binding cassette (ABC) transporters constitute a
family of transport proteins that couple the energy of ATP
hydrolysis to the translocation of a wide variety of substrates,
such as ions, proteins, sugars, amino acids and lipids, across
biological membranes (10,11). In peroxisomes, four genes
coding for ABC transporters have been identified (ABCD1 to
ABCD4). Mutations in ABCD1 results in X-linked adreno-
leukodystrophy/adrenomyeloneuropathy (X-ALD/AMN) (12).
To date, no human disease has been attributed to defects in
the genes coding for ALDRP (ABCD2), PMP70 (ABCD3) or
PMP69 (ABCD4). Patients with X-ALD are characterized bio-
chemically by elevated levels of VLCFA because of a defect
in peroxisomal b-oxidation of VLCFAs. Because of the bio-
chemical phenotype of X-ALD patients, it has been postulated
that the product of the ABCD1 gene, i.e. ALDP, may import
VLCFAs into the peroxisome. This is supported by the obser-
vation that yeast lacking one or both of the two yeast ABCD
transporters (Pxa1p and Pxa2p) have elevated VLCFA levels
(13,14). The functions of the three other transporters in
higher eukaryotes are unknown, but their sequence homology
(88% for ABCD1 and ABCD2; 66% for ABCD1 and ABCD3
or ABCD4) indicate that they might exert related or overlap-
ping function(s) in peroxisomal fatty acid metabolism. For
instance, PMP70 and ALDRP have been shown to compensate
for the loss of ALDP when overexpressed in vitro (15,16).
However, the intrinsic function of PMP70 as evaluated in
abcd32/2 mice, has recently been reported to be related to
the catabolism of middle- and branched-chain fatty acids
(pristanic and phytanic), in the absence of VLCFAs accumu-
lation (17). Similarly, inactivation of abcd2 does not lead to
accumulation of VLCFAs in nervous tissues, although its
stable overexpression by transgenesis in the ALD knoc-kout
mouse prevents accumulation of VLCFAs as well as the
onset of neurological phenotype (18), which indicates that
ALDRP is indeed able to take over from ALDP, at least
when overexpressed. In the present study, we set up to
explore in-depth the intrinsic role of ALDR.
RESULTS
Generation of abcd2 null mutant mice (abcd22/2)
Mouse strains with a targeted deletion of exons 4–6 of the
mouse abcd2 gene (Fig. 1A) were generated from two inde-
pendent ES clones (Material and Methods). To verify that
the targeted genetic disruption of abcd2 resulted in a null
allele, we performed RT-PCR experiments and ALDRP
protein analyses with a C-terminal antibody, as described sub-
sequently (18). Western blots showed a complete absence of
the protein in all tissues of abcd22/2 mice (Fig. 1D). Quan-
titative RT-PCR confirmed the absence of full-length abcd2
mRNA, although shorter, smir-type and low expressed frag-
ments could be detected, consistent with nonsense-mediated
mRNA decay process (data not shown). Absence of the
abcd2 gene was not accompanied by compensatory increases
of its closest paralog, the abcd1 gene, as evidenced by quan-
titative PCR experiments on whole extract CNS, PNS,
adrenal gland and testis samples (data not shown).
The progeny derived from the two ES clones were kept
independent and used separately in the study. Because the
results were identical, the experimental data obtained with
both strains were combined. Mice lacking the abcd2 gene
were delivered in expected Mendelian ratios, were viable
and fertile and did not show any obvious abnormalities in
development, behavior or gross morphology of the nervous
system up to 6 months (data not shown).
Figure 1. Abcd2 knock-out strategy and construct. (A) Wild-type endogenous
mouse Abcd2 locus. DNA targeting construct used for gene targeting in ES
cells to create a knock-out allele, lacking exons 4–6 and harboring the neomy-
cin cassette (Neo) after site-specific recombination. A modified neomycin cas-
sette was inserted, replacing the coding portions of exons 4–6. (B) Southern
blot analysis demonstrating homologous recombination at the Abcd2 locus
in mouse tail genomic DNA. Southern blots are shown using an external flank-
ing probe on EcoRI digested genomic DNA. (C) PCR fragments for mouse
genotyping. (D) Western blot analysis of ABCD2 protein in lysates of cerebel-
lum and testis, prepared from aldr2/2 mice and wild-type littermates.
g-Tubulin is used as loading control.
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Expression pattern of abcd1 and abcd2 genes
We have shown in a previous study that the expression of both
transporters was mirror-like or complementary in adrenal
gland and testis. In the brain, abcd2 mRNA was detected
mainly in pyramidal and granular cell layers of dentate
gyrus and cerebral cortex. The inner granular and Purkinje
cell layers in cerebellum were also strongly labeled for
abcd2. In contrast, abcd1 expression was essentially restricted
to glial and endothelial cells (19). Here, we aimed at refining
abcd2 mRNA expression pattern during embryonic life and
in early adulthood (Fig. 2). Abcd2 appears well expressed in
dorsal root ganglia (DRG) (sensitive peripheral neurons) in
early embryonic stages (E11 and 5) (Fig. 2A) and in prolifera-
tive neuronal layers from cerebral cortex and neuro-olfactory
epithelium at mid-embryonic stages (Fig. 2C, E and F, at
E14 and 5). In adult spinal cord and pons, motor neurons,
interneurons and basal ganglia are strongly positive for
abcd2 (Fig. 2G and H). In summary, abcd2 is widely
expressed in different types of neuronal populations, from
embryonic sensitive neurons of DRGs to mature differentiated
spinal motor neurons. In contrast, abcd1 exhibited a low and
ubiquitous expression pattern throughout development into
adulthood, without being excluded from neurons.
Behavioral deficits in ALDRP-deficient mice
To assess the neurological consequences of ALDRP/ABCD2
absence, mutant animals were analyzed using a variety of
motor skills and behavioral tests. Although no overt clinical
phenotype was observed at 6 months, mice lacking ALDRP
displayed progressive behavioral deficits, consistent with
ongoing neural degeneration from 12 months onwards. The
most striking abnormalities were found in the areas of
balance, coordination and reflexes. The rotarod test was used
as a measure of motor balance, coordination and control.
When compared with wild-type littermates at 12 months of
age, abcd22/2 mice displayed a marked impairment in
their performance during 4 days trial on the rotating rod set
at an accelerating speed (P , 0.01 by ANOVA) (Fig. 3B).
Abcd1-mice performed similar to their wild-type littermates
at this age (data not shown). Latter in life, around 20
months, cohorts of mice from all genotypes were again chal-
lenged. The performance of abcd2 null mice was even more
impaired, and a slight whole body tremor suggestive of cer-
ebellar involvement was apparent in three out of 14
abcd22/2 mice and in eight out of 11 abcd12/abcd22/2
double mutant mice. Data are in agreement with the rotarod
experiments reported in a former study (18) (data not shown).
We studied spontaneous locomotion and exploratory beha-
vior in the open field at 12 months of age. Surprisingly,
despite their impaired performance in rotarod tests, abcd22/2
null mice were significantly more active than their wild-type
littermates. This was especially apparent after the first 5-min
period (Fig. 3A). This finding is indicative of a lack of habitu-
ation capacity to a new environment. Interestingly, abcd1
knock-out mice and particularly double mutants exhibited a
Figure 2. Ald and Aldr RNA expression in early and mid-embryonic stages (A–F) and adult pons and spinal cords (G–L). (A) Aldr is strongly expressed in
DRGs at E11 and 5. Proliferative neurons in cortex (C and E) and neuro-olfactive epitelium (F) are strongly positive for aldr at E14 and 5. In adult stages (weeks
5–6), aldr is expressed in interneurons of pons (G) and spinal cord (H). In contrast, the ald gene exhibits a low and ubiquitous expression pattern, throughout
embryonic development (B and D) and adult pons (I) and spinal cord (J).
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Figure 3. Aldr2/2 mice present a progressive neurological phenotype. (A) Open-field experiments showing lack of habituation of aldr2/2 mutants at 12
months of age (n ¼ 8 wt and n ¼ 12 aldr2/2). (B) Rotarod analysis of mutants versus control littermates, same age (C and D, bar cross test). (C) The time
spent to cross the bar. (D) The number of slips. Aldr2/2 slipped away more often than their wild-type littermates and ald-mice. Double mutant animals
show delayed time to cross the bar and increased number of slips. (E) Electromyographical measurements of the spinal somatosensory evoked response
(H-wave or reflex wave) in aldr2/2, ald2 and double mutant versus control littermates at 12 and 20 months of age. The absence of H-wave is aldr dependent.
(F) Capacity of adult fibroblasts to b-oxidize C26:0, expressed as picomoles per hour per milligram of protein. Wild-type levels have been set to 100. Ald2 and
double mutant fibroblasts show similar reduction to 60% of the wild-type level (P, 0.0008). (G and H) Quantification of saturated VLCFA levels by ESI-MS in
adult fibroblasts and DRG samples, expressed as micromoles per milligram of protein. Wild-type levels have been set to 100. (Single asterisk) Significant
difference versus wild-type. (Double asterisks) Significant difference versus ald2 samples (when ald2 is different against wild-type). All statistics by
ANOVA (Statview Package 5, significance set at P, 0.01).
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decline in deambulation activity when compared with wild-
types, and significantly poorer rearing behaviors, latter in
life (20 months) (18).
At 15 months of age, the time required for mice to reach a
platform along a balance bar was significantly increased in
abcd12/abcd22/2 double mutants (P , 0.001) (Fig. 3C).
Both abcd22/2 and abcd12/abcd22/2 mice exhibited a
marked tendency to slip off the bar, a sign of ataxia
(Fig. 3D), and often failed to maintain balance and fell.
Instead of walking and maintaining a stable upright posture,
they displayed ventral recumbence, with their entire body
flattened against the surface of the bar, and their hind and
fore limbs wrapped laterally around the bar. They used
their fore limbs to drag themselves along the beam, being
their hind limbs generally not used. This sign was particularly
evident in double mutant mice. At 20 months of age, six out of
11 double mutant mice were not able to perform the test,
because they ‘froze’ or fell repeatedly from the bar (data not
shown). These subsets of mice that showed a more severe phe-
notype exhibited, in addition, exaggerated bilateral extension
of fore and hind limbs when suspended by their tails. We
detected postural hypotonia, characterized by animals lying
flat on their abdomen with fore and hind limbs splayed later-
ally. Because this effect could be caused by inhibition of
postural muscle tone (20), we measured muscular strength
with a dynamometer. No difference could be demonstrated
between mutants and controls (data not shown), thus exclud-
ing any gross influence of muscle weakness on their rotarod
or bar cross performance.
Defective spinal reflex in abcd22/2 mice
We assessed function of the peripheral nervous system by
electromyographical exploration after somatosensory stimu-
lation of the sciatic nerve. ALDP deficient mice present
altered motor and sensitive conduction velocities (21). These
deficits were not found in abcd2 mutants. Here, we investi-
gated an additional parameter, the spinal somatosensory
response or spinal reflex (H-wave amplitude). At 12 months
of age, abcd22/2 mice present lower amplitude of the
H-wave than their wild-type littermates (Fig. 3E). Latency
of the H-wave is normal at that age, but diminishes with age
(Fig. 3E). In contrast, this loss of spinal reflex is not presented
by abcd1 mutants, which have values comparable to wild-
types even at older ages. Double mutants exhibit comparable
deficits in amplitude and latency parameters to abcd22/2
mice. These results indicate that the large proprioceptive
sensory neurons at DRG or their afferents are functionally
defective and are consistent with ataxia and loss of propiocep-
tion evidenced at the bar cross and rotarod tests.
Biochemical function of ALDRP
Given the high sequence homology and the differential
expression pattern of both proteins, we speculated that
ALDP and ALDRP could play similar or overlapping bio-
chemical functions in different cell types. Indeed, upon over-
expression, ALDRP has been shown to compensate for ALDP
loss in vitro and in vivo. In X-ALD patient fibroblasts, transi-
ent overexpression of ALDR cDNA corrects the biochemical
defect and transgenic overexpression of ALDRP in abcd1-
mice prevents the VLCFAs accumulation in target tissues
(18). However, saturated VLCFAs do not accumulate in
adult brain, spinal cord and sciatic nerve of abcd22/2 mice
(18). Here, we have investigated saturated VLCFA levels
and C26:0 b-oxidation capacity on adult fibroblasts derived
from our different mouse mutants. In this cell type, lack of
ALDRP is neither translated into an accumulation of
VLCFAs nor into a decrease of C26:0 b-oxidation capacity
(Fig. 3G and H). Interestingly, double mutant fibroblasts
accumulate higher levels of C26:0 than abcd1-fibroblasts
(P , 0.001). In addition, C24:0 levels are higher in double
mutants than in wild-type or abcd1-fibroblasts (P , 0.01).
This suggests that abcd2 might cooperate or compensate to
some extent for abcd1 loss of function. This functional com-
pensation does not occur through of an increase of abcd2
expression at the mRNA or protein levels (data not shown).
Seeking for an alternative consequence of ALDRP loss of
function different from VLCFAs accumulation, we set out to
determine levels of other peroxisomal metabolites. We quan-
tified phytanic and pristanic acids in plasma and liver and
the plasmalogens C16:0 DMA and C18:0 DMA in red blood
cells. We also quantified levels of monounsaturated fatty
acids from the v9 series (C16:1, C18:1, C20:1, C22:1,
C24:1) and polyunsaturated long-chain fatty acids from the
v3 (C18:3, C18:4, C20:5, C22:5, C22:6), v6 (C18:2, C18:3,
C20:2, C20:3, C20:4, C22:2, C22:4, C22:5) and v7 (C16:1,
C18:1, C20:1) series in brain and plasma. We could not evi-
dence any significant difference between abcd22/2 and
their wild-type littermates (data not shown).
The high expression levels of ALDRP in DRG and the
defective spinal reflex of abcd22/2 highlight this particular
cell population as a target to identify a biochemical phenotype
(90% of the cells in DRGs are neuronal bodies). We dissected
DRGs from 5- to 6-day-old pups of abcd22/2 and wild-type
littermates and quantified VLCFAs. We could indeed detect an
accumulation of C26:0 in DRGs from abcd22/2 mice
(Fig. 3I and J, P , 0.002). For comparison, we also analyzed
DRGs from abcd12/2 and abcd1/abcd22/2 double mutants.
Double mutants showed similar VLCFA levels than
abcd22/2 mice. DRGs of abcd12/2 animals also showed
slightly increased levels of C26:0, however, without reaching
statistical significance. Thus, in DRGs, abcd2 seems to play
the same role regarding C26:0 import/catabolism that abcd1
plays in most tissues.
Peripheral and central pathologies are associated
with the neurological phenotype
Analysis of DRG cell number and size from semithin sections
did not yield a significant difference between the abcd22/2
mice and their wild-type littermates either at 12 or 20 months
of age (data not shown). However, electron microscopy exam-
ination revealed a specific pattern of degeneration, more
evident at 20 months of age. Both in satellite cells and
ganglia neurons, the accumulation of residual and zebra-like
bodies was prominent (Fig. 4A). A significant number of
mitochondria showed degenerative images and contained
lipidic inclusions (Fig. 4C–E). We observed disturbed endo-
plasmic reticulum and Golgi apparatus, with dilatation and
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fragmentation of channels and cisterns (Fig. 4C). The number
of lysosomes was increased significantly, suggesting a high
activation of the degradation processes. We encountered
frequently axonal degenerative features, including axolemma
decompactation (Fig. 4F–I).
In spinal cord dorsal and ventral columns, histological
abnormalities not demonstrable at 12 months of age became
evident in abcd22/2 mice at 20 months of age. Analysis of
semithin sections showed fields of axonal spheroid degener-
ation comparable to those observed in abcd12/2 knock-out
mice (21) (data not shown). Axonal degeneration and regener-
ation processes were often encountered in the form of axonal
sprouting (Fig. 5A), consistent with findings of onion bulbs in
sciatic nerve (Fig. 5B). Golgi apparatus fragmentation in the
form of tubulo-vesicular inclusions was found in axons and
neuronal cell bodies (Fig. 5C–E). Mitochondria abnormalities
were frequent (Fig. 5E and G), as well as focal accumulation
of organelles, a sign of disturbed axoplasmic flow (Fig. 5F).
We then studiedthe dorsal columns of the spinal cord by
immunohistochemical techniques. By Sudan black staining,
we commonly evidenced axonal swellings (Fig. 6G and H),
lesions that were often filled with ubiquitinated APP and
synaptophysin accumulations, as revealed by analysis of
serial sections (Fig. 6E–F and I–L). As a consequence,
reactive astrogliosis appeared (Fig. 6A–D). The first signs
of pathology were detected at 12 months in spinal cords and
consisted on APP and synapthophysin accumulations in
Figure 5. Pathological features in spinal cord, ventral horn gray matter of
aldr2/2 mice at 20 months of age, except (B). (A) Axonal sprouting
within a large axon filled with neurofilaments (nf) surrounded by myelin
sheath (ms), lipid droplet (ld). (B) Axonal sprouting consistent with axonal
regeneration in sciatic nerve. a: axon; s: Schwann cell nuclei. (C) Dense,
degenerating axoplasm focally surrounded by distorted myelin. (D) Higher
magnification of the region within the square in (C), showing tubulo-vesicular
inclusions (tvi) and fragmented smooth ER (asterisk). ms: myelin sheath. (E)
Motor neuron cell body with hypertrophy of abnormal Golgi (g) cisternae
associated to fragmented smooth ER (asterisk). Mitochondrial enlargement
and densification of cristae (arrows). (F) At the image center, enlargement
of a non-myelinated fiber, with accumulation of organelles. Note myelinated
degenerating axons, with decompactation of axolemma (asterisk). (G) In
neurons, lamellar bodies derived from altered Golgi (g) and rough endo-
plasmic reticulum (arrows). Note mitochondria with tubular cristae (asterisk)
and ring-shaped alteration (white arrow). (H) Remnants of the Golgi
apparatus in the form of lamellae (arrows), in a zone with small smooth ER
vacuoles. Two lamellated bodies within an axonal fiber (open arrows).
Scale bars: 1 mm (A–C, E and F); 0.1 mm (D); 0.5 mm (G and H).
Figure 4. Pathological features on DRG cells in aldr2/2 mice at 20 months
of age. (A) High number of zebra bodies filling up a satellite cell (s). a: axon
containing electron dense debris; n: ganglion cell nucleus. (B) Polymorphous
residual and zebra-like bodies in cytoplasm of a ganglion cell (arrows). (C)
Abnormal mitochondria with a lipid droplet and circular cristae in a ganglion
cell (m). Fragmentation of Golgi cisternae (g). rb: residual body. (D) Mito-
chondria containing lipidic residual bodies in satellite cells. (E) In a ganglio-
nar cell, mitochondria (m) with paracristallin profile (arrow) resulting from the
juxtaposition of parallel-stacked cristae. In the vicinity, a lipid droplet (Ld)
with an accumulation of filamentous, proteinaceous material. (F) Decompacta-
tion of axolemma (arrow). (G) Axonal degeneration: involution of the cellular
organites with the formation of a fibrillar body (f) and myelin-like bodies
(arrow); numerous vacuoles. Empty fiber (asterisk). (H) Myelin remnants in
the Schwann cell, resulting in a fibrillar and granular body (f). Axolemma
decompactation (arrow). Note two giant mitochondria (asterisks). (I) An
empty myelinated fiber containing two myelin bodies. Scale bars: 1 mm
(A and B); 0.1 mm (C–E); 0.5 mm (F–I).
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axonal swellings. The same type of immunostanings used for
the spinal cord were used for the brain, without revealing any
significant difference to wild-type littermates. Neither Nissl-
staining could detect major neuroanatomical alterations. All
brain nuclei were present and not markedly different from
the wild-type littermates, indicating normal brain development
in the abcd22/2 mice (data not shown).
Ataxia is commonly attributed to altered output from the
cerebella cortex or from deep cerebella nuclei (22). Given
the ataxic phenotype of the abcd22 /2 mice, we examined
the cerebellum, using histological stainings (Nissl). At 12
months of age, the abcd22/2 cerebellum showed no major
changes in appearance of the molecular, Purkinje cell and
granule cell layers, as well as normal foliation and cytoarchi-
tecture (data not shown). However, at 20 months of age, we
detected gaps in the Purkinje cell monolayer in Nissl-stained
sections (Fig. 7A and B). Immunohistochemistry against cal-
bindin (D28-K) confirmed atrophy or death of Purkinje cells
(Fig. 7C and D). A clear reduction of non-phosphorylated neu-
rofilaments in Purkinje cells (SMI 32 antibody) (23) indicated
reduced dendritic arborization (Fig. 7E and F). Fibrillary
acidic protein (GFAP)-staining revealed an increased fre-
quency of local spots of GFAP upregulation in the molecular
layer of the cerebellum (Fig. 7E and F). These GFAP ‘hot-
spots’ are likely to indicate a local degeneration of Purkinje
cells with concomitant local reactive gliosis.
It is noteworthy that all the pathological changes noticed
by ultrastructural or immunohistochemical techniques in
abcd22/2 mice at DRGs, spinal cords and cerebellar sites
were presented in the same extent, intensity and age by
abcd1 deficient mice. Double mutants showed a more severe
involvement and earlier onset of pathological signs, evidenced
from 12 months onwards.
DISCUSSION
We present a model of late-onset, slowly progressive neuronal
degeneration presumably caused by chronic accumulation of
VLCFAs and/or other lipid metabolites due to ALDRP/
ABCD2 inactivation.
On the basis of close sequence homology between
abcd2/aldr and its paralog abcd1/ald, functional redundancy
has been repeatedly suggested from the moment of its identi-
fication (24). Indeed, abcd2 is able to correct the VLCFAs
accumulation due to abcd1 loss of function when over-
expressed in vitro (15,16) and in vivo (18). In addition, over-
expression of abcd3 corrects VLCFAs levels in vitro, although
its inactivation in the mouse does not lead to VLCFAs
accumulation (17). Similarly, we could not detect higher
levels of VLCFAs in neural tissue of abcd22/2 mice (18),
thus leaving open the question of the true role of abcd2 in
relation to VLCFAs catabolism.
In the current work, we extended the biochemical analysis
further to demonstrate a significant accumulation of
VLCFAs in DRGs of abcd22/2 mice, together with normal
levels of other peroxisomal metabolites. Thus, we present
compelling evidence of a redundant biochemical function
between the two transporters in the mouse. The normal
levels of VLCFAs in brain and spinal cords of abcd2
mutants may be due to the fact that low numbers of cells
express ALDRP (only one-fourth of the cells in total CNS
homogenates are neurons, whereas 90% of the cells in
DRGs are neurons), or alternatively, that its biochemical
role regarding VLCFAs transport is quantitatively less import-
ant at the precise time point of analysis (8 months in whole
neural tissue homogenates versus 5-day-old DRGs). It is
worth noting that this biochemical abnormality in DRG
neurons in abcd22/2 newborns correlates with a differential
electromyographical phenotype against abcd1-deficient mice
in adulthood. Indeed, ALD mice neither significantly
Figure 6. Gliosis, myelin and axonal pathology in spinal cord in aldr2/2.
Longitudinal sections of the dorsal spinal cord in wild-type and aldr2/2
and control littermates at the age of 20 months, processed for glial GFAP,
lectin L. esculentum, APP, Sudan black and synaptophysin. (A–D) Reactive
astrogliosis is observed in aldr2/2 mice when compared with littermate con-
trols. In (E and F), APP deposits are seen in axonal swellings in aldr2/2
mice. This is accompanied by lipidic debris of myelin, as revealed with
Sudan black in (G and H). In (I and J), abnormal fibers filled with synapto-
physin are found in aldr2/2 mice. Synaptophysin and APP deposits are
ubiquitinated (K and L).
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accumulated VLCFAs nor presented altered H-waves. The
contrasting electromyographical phenotypes of abcd1- and
abcd22/2 mice illustrate the complementary functions
shared by the two transporters.
We face a different scenario when analyzing mouse fibro-
blasts. Most likely, because expression levels of abcd2
mRNA are rather low, inactivation of abcd2 neither leads to
impairment of b-oxidation capacity nor to accumulation of
VLCFAs. However, in a double mutant abcd12/abcd22/2
context, accumulation of VLCFAs is significantly higher
than in single abcd1- mutants, without additional impairment
in peroxisomal degradation capacity. This might indicate
that in this particular cell type and in the absence of
ABCD1, ABCD2 is involved in a metabolic pathway other
than degradation of VLCFAs, which leads to a secondary
accumulation of VLCFAs. This is in agreement with results
provided in McGuinness et al. (25), where the authors find
normal VLCFAs b-oxidation levels in ALD mouse tissues
and thus claim that the relationship between ALDP function
and VLCFA metabolism is merely indirect.
Our findings demonstrate that loss of abcd1, the gene
responsible for a demyelinating disease, leads to axonal
degeneration, with degenerative features compatible with
axonal transport impairment and to Purkinje cell loss in
mice. This comes as no surprise if we consider that even in
primary myelin disorders, such as multiple sclerosis (26), or
Figure 7. Cerebellar pathology in aldr2/2 mice at 20 months of age. (B) Loss of Purkinje cell somata evidenced by Nissl staining (arrowheads). (D) Focal loss
of staining with anti-calbindin D28K in the aldr2/2 mice. (F) Focal upregulations of GFAP expression in aldr2/2. (H) Strong reduction of non-phosphorylated
neurofilaments in Purkinje cells was seen by staining with anti-SMI32. (A, C, E and G) Images from wild-type littermate controls. Scale bar: 50 mm.
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in the absence of a major myelin protein CNPase axonal loss
occur (27). Those axonal swellings and degeneration have
consequently been attributed to loss of oligodendroglia/
myelin support. Thus, oligodendrocytes communicate in
some way with the underlying axon and support axonal func-
tion. In contrast, inactivation of its predominantly neuronal
expressed paralog abcd2 leads not only to the same type of
phenotype, neuronal and axonal degeneration but also to astro-
cyte activation and gliosis. Along with these lines, at the histo-
pathological level and by the means we have used, it has not
been possible to clearly discriminate between the phenotypes
of both mutants. Abcd1 and abcd2 deficient mice present
very similar (in quality and quantity/number and morphology)
accumulations of APP and synaptophysin in axonal swellings,
astrogliosis in spinal cord and cerebellum and loss of Purkinje
cells in cerebellum, despite the lack of detectable abnormal-
ities in the cerebral cortex.
It is through neurological and electrophysiological testing
that we can discriminate between the roles of both transpor-
ters. Abcd22/2 mice present defective spinal reflexes and
ataxic phenotype, similar to the mouse models of Friedreich
ataxia or vitamin E deficiency (28,29), at an age when
Abcd1-mice still do well. The differences in expression
pattern most likely account for a differential vulnerability/
different target cellular populations, thus resulting in a differ-
ent phenotypic outcome. Although abcd1 and abcd2 genes
demonstrate functional redundancy that extends beyond their
shared biochemical roles, abcd22/2 mice display abnormal-
ities not observed in abcd1-mutant mice, revealing that
abcd1 and abcd2, or their genetic regulation, are not equival-
ent. For instance, the hyperactivity/lack of habituation pheno-
type displayed by aldr2/2 mice deserves further study, as
disturbance of higher cognitive functions could be underlying
this pathological feature. Taking all pathological findings
together, we conclude that abcd22/2 mice develop a late-
onset spinocerebellar ataxia, with impaired propioception
most likely due to neuronal degenerative processes at the
DRG level or to synaptic defects in spinal cord. To date, no
human syndrome compatible with this phenotype has been
linked to the ABCD2 locus at 12q1.1–1.2. Thus, description
of the phenotype in mice might contribute to identifying
patients suffering from a similar condition, i.e. an autosomal
recessive peripheral neuropathy with cerebellar involvement,
but without elevation of VLCFA in plasma or fibroblasts.
An interesting feature found in both ALD and ALDR mouse
models is the presence of ultrastructural alterations of mito-
chondria in axons and neuronal bodies. The degradation of
fatty acids in mammals takes place in mitochondria and per-
oxisomes. Very-long-chain and certain branched-chain fatty
acids are first chain-shortened in peroxisomes, and sub-
sequently, oxidized to completion in mitochondria via the
b-oxidation pathway. A growing body of evidence suggests
that mitochondria is playing a significant role in the patho-
genesis of peroxisomal disease and that a relevant cross-talk
connects both organelles. For instance, b-oxidation activity
for VLCFAs is still present to 60% in patients and mouse
ALD-deficient fibroblasts (30–32); it is surprisingly normal
in mouse tissues lacking ALDP (25) and even still present
up to 20% in some cases in Zellweger patients fibroblasts
(Wanders, personal communication). These findings are
consistent with an overlapping or compensatory role
between both organelles. Indeed, mitochondrial anomalies are
observed in liver of mice with a total ablation of peroxisomal
b-oxidation (inactivation of multifunctional proteins 1 and 2)
(33). Moreover, functional and ultrastructural mitochondrial
abnormalities have been found in the liver of a Zellweger syn-
drome mouse model (34,35), as well as in human Zellweger
syndrome, including lipidic inclusions (36). Recently, the
mitochondrion has also been implicated in the pathogenesis
of X-ALD in mice and human. Lipidic intramitochondrial
inclusions have been observed in atrophic neurons of DRG
in patients with AMN, the adult form of X-ALD (37). Func-
tional and structural alterations of mitochondria in adrenal
cortex as a result of loss of ALDP are found in the X-ALD
mouse model (25). These lipidic inclusions and condensation
of cristae resemble the anomalies we have found in the
neural tissue of both ALDP and ALDRP deficient mice.
These signs of mitochondrial stress may reflect an attempt
of the organelle to ‘back-up’ for the impaired peroxisomal
function or simply an overload of the mitochondria with sub-
strates that should have been degraded in peroxisomes. Defec-
tive mitochondria may lead to a failure of ATP-dependent
axoplasmic transport with consequent ‘dying-back’ axonal
degeneration. Indeed, structurally abnormal mitochondria in
affected axons are associated with segmental axonal swelling
and impairment of anterograde and retrograde transport in a
mouse model of HSP (38). Mitochondrial damage has also
been found associated with aberrant sprouting and synapse
loss in AD and dementia with Lewy bodies (39). In our
models, the presence of axonal swellings that accumulate
neurofilaments and organelles suggests a similar pathogenetic
mechanism. In addition, prominent in the ALD and ALDR
mouse models is the tubulo-vesicular inclusions derived
from endoplasmic reticulum and Golgi fragmentation. Inter-
estingly, fragmentation of Golgi apparatus is found in sporadic
amyotrophic lateral sclerosis (40,41) and in mouse models of
tauopathies, where it has been associated with neuronal
atrophy and non-apoptotic cell death (42). Thus, the neuro-
degenerative features we have identified in ALD and ALDR
mouse models placed them in a common path with other
major neurodegenerative diseases.
The link between defective VLCFAs catabolism and patho-
genesis is not obvious in X-ALD. The incorporation of excess
of VLCFAs into cell membranes might impair membrane
stability (43) or perturb their microenvironment, resulting in
dysfunction and death of vulnerable cells (44,45). Others
showed that cells exposed to C26:0 produce higher levels of
reactive oxygen species (46). While this article was in prep-
aration, a direct correlation between accumulation of saturated
VLCFAs in brain white matter and disease severity in human
X-ALD patients has been reported, shedding some light into
the issue (47). Thus, accumulation of VLCFAs in DRGs of
abcd22/2 mice may increase the vulnerability to this particu-
lar cellular population to neurodegeneration. VLCFAs are
found as lateral chains of complex lipids, such as phospha-
tidylcholine or phosphatidylethanolamine, thus playing a
main structural role as components of cellular membranes.
In neural membranes, a strict balance between free and ester-
ified fatty acids is necessary, not only for normal membrane
composition, integrity and function but also for the optimal
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activity of the membrane-bound enzymes, receptors and ion
channels involved in normal signal-transduction processes.
We propose that the composition, maintenance or recycling
process of myelin and neuronal/axonal membrane might be
disturbed in the ALD and ALDR models, leading to impaired
axono-glia communication, which would be detrimental for
both interconnected compartments. Crucial to understanding
of ALD and ALDR pathogenesis is to elucidate the mechanisms
by which impaired peroxisomal function(s) or VLCFAs
accumulation results in axonal degeneration, with features com-
patible with axonal transport impairment. VLCFAs levels have
been found to be increased in X-ALD brain gangliosides (48),
which might contribute to pathogenesis. Another plausible
link may focus on the proteolipid protein (PLP/DM20), the
main component of CNS myelin, accounting for .50% of
the total protein of this membrane. PLP is a palmitoylated
protein that contains mainly palmitic, oleic and stearic acids
covalently bound as acyl chains. In adrenoleukodystrophy
patients, the proportions of saturated VLCFAs bound to PLP
have been found to be increased at the expense of oleic acid
(49). Because covalently bound fatty acids contribute to the
tertiary structure of PLP in aqueous medium (50), this altered
fatty acid composition may influence its physical or biological
properties, compromising stability of PLP itself or its insertion
in the myelin sheath. Indeed, recent evidence indicates a severe
impairment of fast axonal transport system in the PLP/DM20
deficient mouse (51), thus underscoring the importance of a
healthy membrane for axonal function.
MATERIALS AND METHODS
Mouse generation, breeding and genotyping
The abcd2–/– mice were generated by inactivation of the
abcd2 gene by classic homologous recombination. The abcd2
genomic sequence was isolated from a 129 mouse genomic
library. Two fragments of the abcd2 gene were cloned into a
pPNT backbone vector that contained a neomycin selection
cassette flanked by LoxP sites (Fig. 1A). The linearized target-
ing vector was transfected into male R1 embryonic stem cells
derived from 129 mouse strain. Double selection was per-
formed with G418 and ganciclovir, and drug-resistant clones
were screened for homologous recombination by Southern
blotting (Fig. 1B). We obtained three recombinant clones,
out of 302, resistant to neomycin, which were injected into
blastocysts from C57BL/6 mice. Chimeric male pups were
bred with C57BL/6 females to confirm germ-line trans-
mission. DNA extracted from tails was used for PCR-based
genotyping, using standard protocols. Primers used for
genotyping were as follows: a common primer (50-GAG
CTAGTGTCATTGTTCTG-30) used together with a WT-
specific (50-TAACCTGCTAGTTCAGTGAT-30) or a KO-
specific (50-TGCAATCCATCTTGTTCAATG-30). The abcd1
gene inactivation has been described (30). To obtain double
heterozygous mutants, we crossed abcd12/þ females with
abcd22/2 mice. Double heterozygotes were intercrossed to
obtain double knock-out mice and wild-type littermate con-
trols; the offspring obeyed Mendelian ratios. Results described
in this manuscript are derived from mice on a mixed C57BL/
6J/129Sv background (87% C57BL/6J and 13%129Sv).
Crucial experiments (locomotor tests and EMG) have been
confirmed with pure C57BL/6J background mice. Histology,
morphometric, behavioral testing and electrophysiological
experiments were performed in a blind way with respect to
the animal’s genotype. All methods employed in this work
are in accordance with the Guide for the Care and Use of Lab-
oratory Animals published by the US National Institutes of
Health (NIH Publications no. 85-23, revised 1996).
Behavior tests
All experiments were performed with naı¨ve male animals,
which were kept on a 12 h light/dark cycle.
Open field and rotarod tests
Coordination, balance and motor skill acquisition were tested
using an accelerated rotaring rod (Panlab, Barcelona, Spain)
test, as described previously (21). In brief, mice were placed
on the rod in a routine of four trials per day for a period of 4
days. The rod accelerated from 4 to 40 r.p.m. in 5 min and
remained at maximum speed two more minutes. Animals
were scored for their latency to fall (in seconds) for each trial
and rested a minimum of 10 min between trials to avoid exhaus-
tion. Results were analyzed by a repeated-measure ANOVA
test, considering three factors: days (fixed), genotype (fixed)
and animals (variable), nested in genotype and crossed with
days. Spontaneous ambulation in an open field was recorded
during a 15 min period as described (21).
Horizontal bar cross test
The bar cross test is carried out using a wooden bar of 100 cm
in length and 2 cm in width (diameter). This bar is just wide
enough for mice to stand on with their hind feet hanging
over the edge such that any slight lateral misstep will result
in a slip. The bar is elevated 50 cm from the bench surface,
so that animals do not jump off, yet are not injured upon
falling from the bar. To eliminate the novelty of the tasks as
a source of slips, all animals were given four trials on the
bar at the beginning of the testing session. By the fourth
trial, control animals ran the bar with not more than two
slips. In the experimental session, the number of hind limb
lateral slips and falls from the bar and the time to reach the
platform were counted on four consecutive trials. If an
animal fell, it was placed back on the bar at the point at
which it fell and was allowed to complete the task. The bar
was cleaned with ethanol after each animal had crossed it.
Fibroblast culture and biochemical measurements
Primary fibroblast cultures were derived from mutant mice
and their control littermates and grown at 378C in 5% CO2
in DMEM, supplemented with fetal calf serum (10%), penicil-
lin (100 U/ml) and streptomycin (100 U/ml). Cultures were
grown to confluence on monolayer. Fatty acid b-oxidation
was determined by measuring the capacity of the intact cells
to degrade 141-C-labeled fatty acids (C26:0) to water-soluble
products, essentially as described (52). Specific activity was
expressed as picomoles of 14CO2 released per hour per
3574 Human Molecular Genetics, 2005, Vol. 14, No. 23
milligram of protein. Total cellular VLCFAs fatty acids were
analyzed using electrospray ionization-tandem mass spec-
trometry (ESI-MS), as described recently (53). Branched-
chain fatty acids in plasma and liver were analyzed using
GC-MS (54). Total monounsaturated and polyunsaturated
fatty acids in brain and plasmalogens in erythrocytes were
measured by GC analysis (55).
Statistical analysis
Data are expressed as mean+ SD. Statistical significance was
evaluated using ANOVA tests (Statview Package 5). The
results were considered significant at P , 0.01.
Electrophysiological recordings
Electromyograms were performed at Neurofit (Strasbourg,
France) using a Neuromatic 2000M apparatus (Dantec, Les
Ulis, France). Mice were anesthetized with intraperitoneal
injection of 60 mg/kg ketamine chlorohydrate (Imalgene
5008; Rhone-Biomerieux, Lyon, France). Distal latency and
amplitude of M- and H-waves were recorded in the plantar
hind paw muscle after sciatic nerve stimulation.
Electron microscopy
Mice were anesthetized as described earlier and perfused with
a 4% PFA and 3% glutaraldehyde (Fluka) in phosphate
buffered (pH 7.4, 0.1 M) solution. Spinal cord, DRG and
cerebrum were dissected and fixed overnight. Tissue was
post-fixed for 1 h in 1% osmium tetroxide in phosphate
buffer, dehydrated in serial ethanol solutions and embedded
in an araldite–epon mixture. Embedded tissues were then
placed at +608C for 2 days to polymerize. Transverse semi-
thin sections, 1 mm in thickness, were prepared with an ultra-
microtome and stained with Toluidine blue. Ultrathin sections
(50 nm) were investigated on a Philips C12-208 electron
microscope at 80 kV.
In situ hybridization
ISH on mouse embryos (whole mounts) and radioactive ISH
on post-natal frozen CNS were performed as described (56).
The antisense RNA probes used contained the whole cDNA
sequence of the abcd1 gene and the C-terminal half of the
abcd2 gene, as previously described (19).
Immunohistochemistry
Mice were perfused with a 4% PFA solution. Spinal cords
were embedded in paraffin and serial sections, 5 mm thick,
were cut in the longitudinal plane with a sliding microtome.
The sections were stained with hematoxylin and eosin,
Luxol fast blue-Klu¨ver-Barrera and Sudan black or processed
for immunohistochemistry to glial GFAP (Dako, rabbit poly-
clonal, 1:500), ubiquitin (Dako, rabbit polyclonal, 1:500),
APP (Boehringer, 1:10) and synaptophysin (Dako, mono-
clonal, 1:500). Lectin Lycopericon esculentum (Sigma,
L-0651, 1:200) was used as a marker for microglial cells.
The sections were incubated with the modified labeled
streptavidin (LSAB) technique (DAKO LSAB2 System
Peroxidase). The number of abnormal specific profiles was
quantified in every tenth section for each particular stain.
Five sections corresponding to the dorsal columns of the
spinal cord were analyzed per animal and per stain. For analy-
sis of the cerebellar pathology, frozen sections were used,
which were incubated as free floating sections with antibodies
against calbindin D28K (Swant, 1:1000), SMI32 (Sternberger
monoclonals, 1:1000) and GFAP (Dako, 1:1000). The staining
was visualized with AlexaFluor 568 secondary antibodies
(Molecular Probes).
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